Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

por Shih, Kent, Arkenau, Hendrik-Tobias, Infante, Jeffrey R.
Publicado 2014

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado 2015

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado 2015

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

por LoRusso, Patricia M., Infante, Jeffrey R., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., Cohen, Roger B.
Publicado 2017

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

por Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.
Publicado 2017

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

por Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.
Publicado 2017

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

por Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Publicado 2013

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado 2015

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

por Kelly, Karen, Infante, Jeffrey R., Taylor, Matthew H., Patel, Manish R., Wong, Deborah J., Iannotti, Nicholas, Mehnert, Janice M., Loos, Anja H., Koch, Helga, Speit, Isabell, Gulley, James L.
Publicado 2018

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

por Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Publicado 2018

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

por Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Publicado 2018

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

por Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, Howard A, Zamboni, William C
Publicado 2015

Accumulation of Extracellular Hyaluronan by Hyaluronan Synthase 3 Promotes Tumor Growth and Modulates the Pancreatic Cancer Microenvironment

por Kultti, Anne, Zhao, Chunmei, Singha, Netai C., Zimmerman, Susan, Osgood, Ryan J., Symons, Rebecca, Jiang, Ping, Li, Xiaoming, Thompson, Curtis B., Infante, Jeffrey R., Jacobetz, Michael A., Tuveson, David A., Frost, Gregory I., Shepard, H. Michael, Huang, Zhongdong
Publicado 2014

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

por Naing, Aung, Infante, Jeffrey R, Papadopoulos, Kyriakos P, Autio, Karen A, Wong, Deborah J, Falchook, Gerald S, Patel, Manish R, Pant, Shubham, Whiteside, Melinda, Bendell, Johanna, Bauer, Todd M, Janku, Filip, Javle, Milind, Colen, Rivka, Tannir, Nizar, Oft, Martin
Publicado 2015

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

por Harding, James J., Telli, Melinda, Munster, Pamela, Voss, Martin H., Infante, Jeffrey R., DeMichele, Angela, Dunphy, Mark, Le, Mai H., Molineaux, Chris, Orford, Keith, Parlati, Frank, Whiting, Sam H., Bennett, Mark K., Tannir, Nizar M., Meric-Bernstam, Funda
Publicado 2021

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado 2013

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

por Smith, David C., Kalebic, Thea, Infante, Jeffrey R., Siu, Lillian L., Sullivan, Daniel, Vlahovic, Gordana, Kauh, John S., Gao, Feng, Berger, Allison J., Tirrell, Stephen, Gupta, Neeraj, Di Bacco, Alessandra, Berg, Deborah, Liu, Guohui, Lin, Jianchang, Hui, Ai-Min, Thompson, John A.
Publicado 2015

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanc...

por Bendell, Johanna C., Kelley, Robin K., Shih, Kent C., Grabowsky, Jennifer A., Bergsland, Emily, Jones, Suzanne, Martin, Thomas, Infante, Jeffrey R., Mischel, Paul S., Matsutani, Tomoo, Xu, Shuichan, Wong, Lilly, Liu, Yong, Wu, Xiaoling, Mortensen, Deborah S., Chopra, Rajesh, Hege, Kristen, Munster, Pamela N.
Publicado 2015

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

por Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C., Safran, Howard, Stinchcombe, Thomas E., Srdanov, Marko, Gelb, Arnold B., Schlichting, Michael, Chin, Kevin, Gulley, James L.
Publicado 2017

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

por Apolo, Andrea B, Ellerton, John A, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael S, Aljumaily, Raid, Gourdin, Theodore, Dirix, Luc, Lee, Keun-Wook, Taylor, Matthew H, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Manitz, Juliane, Pennock, Gregory, Ruisi, Mary, Gulley, James L, Patel, Manish R
Publicado 2020